Clinical Trial

Botulinum Toxin Type A Versus Local Anesthetic Injection for Chronic Neuroma Pain After Combat-Related Amputation

Study acronym: NEUROQUIET
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Patients with combat-related amputations frequently experience persistent neuroma pain that may interfere with rehabilitation, prosthesis use, sleep, mobility, and quality of life. Current treatment options often provide only temporary relief. This study aims to compare two ultrasound-guided injection approaches for chronic neuroma pain after combat-related amputation: botulinum toxin type A and local anesthetic injection. Participants will be randomly assigned to receive one of the two treatments. Pain intensity, neuropathic pain symptoms, phantom limb pain, prosthesis tolerance, and functional outcomes will be evaluated during follow-up visits over a 24-week period. The goal of the study is to determine whether botulinum toxin type A provides longer-lasting pain reduction and improved functional recovery compared with local anesthetic injection in patients with chronic neuroma pain after combat-related amputation.
Trial Details
NCT Number NCT07626983
Lead Sponsor Ukrainian Society of Regional Anesthesia and Pain Therapy
Conditions Chronic Pain Due to Injury, Neuroma of Lower Limb, Neural Injury, Neuroma of Upper Limb, Combat Related Symptoms
Enrollment 100 participants
Start Date 2026-05-30
Primary Completion 2026-12-15 (estimated)
Study Completion 2026-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-06-04